Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Ruiz González, Rubén
  • Milán, Paula
  • Stockert, Juan Carlos
  • Villanueva, Ángeles
  • Cañete, Magdalena
A combination of therapies to treat cancer malignancies is at the forefront of research with the aim to reduce drug doses (ultimately side effects) and diminish the possibility of resistance emergence given the multitarget strategy. With this goal in mind, in the present study, we report the combination between the chemotherapeutic drug doxorubicin (DOXO) and the photosensitizing agent pheophorbide a (PhA) to inactivate HeLa cells. Photophysical studies revealed that DOXO can quench the excited states of PhA, detracting from its photosensitizing ability. DOXO can itself photosensitize the production of singlet oxygen; however, this is largely suppressed when bound to DNA. Photodynamic treatments of cells incubated with DOXO and PhA led to different outcomes depending on the concentrations and administration protocols, ranging from antagonistic to synergic for the same concentrations. Taken together, the results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Ruiz González, Rubén
  • Milán, Paula
  • Stockert, Juan Carlos
  • Villanueva, Ángeles
  • Cañete, Magdalena
A combination of therapies to treat cancer malignancies is at the forefront of research with the aim to reduce drug doses (ultimately side effects) and diminish the possibility of resistance emergence given the multitarget strategy. With this goal in mind, in the present study, we report the combination between the chemotherapeutic drug doxorubicin (DOXO) and the photosensitizing agent pheophorbide a (PhA) to inactivate HeLa cells. Photophysical studies revealed that DOXO can quench the excited states of PhA, detracting from its photosensitizing ability. DOXO can itself photosensitize the production of singlet oxygen; however, this is largely suppressed when bound to DNA. Photodynamic treatments of cells incubated with DOXO and PhA led to different outcomes depending on the concentrations and administration protocols, ranging from antagonistic to synergic for the same concentrations. Taken together, the results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.